XML 62 R32.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Reconciliation of the Company's business segments to the consolidated financial statements
The following table is a reconciliation of the Company’s business segments to the consolidated financial statements: 
In millions
Pharmacy Services
Segment(1)(2)
 
Retail/LTC
Segment(2)
 
Corporate
Segment
 
Intersegment
Eliminations(2)
 
Consolidated
Totals
2016:
 

 
 

 
 

 
 

 
 

Net revenues
$
119,963

 
$
81,100

 
$
—

 
$
(23,537
)
 
$
177,526

Gross profit(3)
5,901

 
23,738

 
—

 
(782
)
 
28,857

Operating profit(4)(5)(6)
4,672

 
7,281

 
(894
)
 
(721
)
 
10,338

Depreciation and amortization
714

 
1,642

 
119

 
—

 
2,475

Additions to property and equipment
295

 
1,732

 
252

 
—

 
2,279

2015:
 

 
 

 
 

 
 

 
 

Net revenues
$
100,363

 
$
72,007

 
$
—

 
$
(19,080
)
 
$
153,290

Gross profit
5,227

 
21,992

 
—

 
(691
)
 
26,528

Operating profit(5)(6)
3,989

 
7,130

 
(1,037
)
 
(628
)
 
9,454

Depreciation and amortization
654

 
1,336

 
102

 
—

 
2,092

Additions to property and equipment
359

 
1,883

 
125

 
—

 
2,367

2014:
 

 
 

 
 

 
 

 
 

Net revenues
$
88,440

 
$
67,798

 
$
—

 
$
(16,871
)
 
$
139,367

Gross profit
4,771

 
21,277

 
—

 
(681
)
 
25,367

Operating profit
3,514

 
6,762

 
(796
)
 
(681
)
 
8,799

Depreciation and amortization
630

 
1,205

 
96

 
—

 
1,931

Additions to property and equipment
308

 
1,745

 
83

 
—

 
2,136

 
(1)
Net revenues of the Pharmacy Services Segment include approximately $10.5 billion, $8.9 billion and $8.1 billion of Retail Co-Payments for 2016, 2015 and 2014, respectively. See Note 1 “Significant Accounting Policies” to the consolidated financial statements for additional information about Retail Co-Payments. 
(2)
Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at the Company’s retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice ® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company’s long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
(3)
The Retail/LTC Segment gross profit for the year ended December 31, 2016 includes $46 million of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(4)
The Pharmacy Services Segment operating profit for the year ended December 31, 2016 includes the reversal of an accrual of $88 million in connection with a legal settlement.
(5)
The Retail/LTC Segment operating profit for the three months and year ended December 31, 2016 includes a $34 million asset impairment charge in connection with planned store closures in 2017 related to the Company’s enterprise streamlining initiative. The Retail/LTC Segment operating profit for the 2016 and 2015 include $281 million and $64 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(6)
The Corporate Segment operating loss for the year ended December 31, 2016 includes $10 million of integration costs. For the year ended December 31, 2015, the Corporate Segment operating loss includes $156 million of acquisition-related transaction and integration costs and a $90 million charge related to a legacy lawsuit challenging the 1999 legal settlement by MedPartners of various securities class actions and a related derivative claim.